Pfizer Delays Generic Vyndamax Until 2031 – Great News for BridgeBio’s Attruby
Pfizer extends Vyndamax patent to 2031, delaying generics and giving BridgeBio more time to grow its rival heart drug without pressure.
/ 181 items
#XY Event-Driven Stocks↓
Rocket Scores $180 Million Cash Boost – Extends Runway to 2028 for Heart Gene Therapies
Rocket Pharma sold an FDA voucher for $180M cash, boosting funds without dilution and extending runway to 2028 for heart gene therapies.
Erasca Stock Crashes on Patient Death — But Analysts Call the Selloff Overdone
Erasca stock fell after a patient died in a cancer drug trial. Analysts say it’s likely a rare case, drug still shows promise.
HyBryte Skin Cancer Drug Fails Key Test – Soligenix FLASH2 Trial Halted
Soligenix stopped HyBryte CTCL trial early as it didn’t work well, though it was safe; company will review data and options.
PFS Triumph or OS Flop? Why CMPX Shares Plunged Despite Positive Cancer Results
Compass Therapeutics fell after cancer drug improved outcomes but failed to show clear survival benefit due to patient crossover.
Veradermics’ Oral Hair Loss Pill Scores Major Win in Late-Stage Trial
Veradermics’ hair pill VDPHL01 showed strong results, growing 30+ hairs/cm in trials, safe, and may become a new baldness treatment.